| 产品详情 |
| Edit |   |
|---|
| Product Name | Dolutegravir |
|---|
| Description | Purity ~90%. Dolutegravir is a second generation HIV-1 integrase strand transfer inhibitor. Dolutegravir is currently in Phase III clinical trials for the treatment of HIV infection. Dolutegravir has been shown to potently inhibit HIV replication in cells such as peripheral blood mononuclear cells (PBMCs), MT-4 cells and CIP4 cells infected with a self-inactivating PHIV lentiviral vector. Solubility: As reported Method for Determining Identity: Proton NMR (DSMO-d6), 19F NMR (DSMO-d6) Spectroscopy and Mass Spectrometric Analysis TLC Conditions: As reported |
|---|
| Size | 2.5mg |
|---|
| Concentration | n/a |
|---|
| Applications | n/a |
|---|
| Other Names | (4R,12aS)-N-[(2,4-Difluorophenyl)methyl]-3,4,6,8,12,12a-hexahydro-7-hydroxy-4-methyl-6,8-dioxo-2H-pyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazine-9-carboxamide; GSK 1349572; S/GSK1349572; |
|---|
| Gene, Accession, CAS # | n/a |
|---|
| Catalog # | 10933 |
|---|
| Price | |
|---|
| Order / More Info | Dolutegravir from UNITED STATES BIOLOGICAL |
|---|
| Product Specific References | n/a |
|---|
| 产品资料 |
|
|